Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp17 | Arthritis and other joint diseases: translational and clinical | ECTS2013

Bone is the main target of activation of Canonical Wnt pathway in osteoarthritis

Funck-Brentano Thomas , Bouaziz Wafa , Geoffroy Valerie , Hannouche Didier , Marty Caroline , Hay Eric , Cohen-Solal Martine

Objective: Wnt/β-catenin pathway is a main regulator of bone remodeling, but might be inhibited in cartilage in osteoarthritis (OA). We here investigated the effect of mechanical loading in Wnt activation and the expression of Wnt antagonists in the joint tissues.Methods: Topgal mice were used. Mice underwent partial meniscectomy (Mnx) and sacrificed at 4, 6, and 9 weeks. Dissected knees were scanned by microCT and then prepared for cryosectioning t...

ba0001pp102 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

A genetic polymorphism of osteocalcin is associated with BMI but not with parameters of glucose and lipid metabolism in women with polycystic ovary syndrome

Schwetz Verena , Trummer Olivia , Giuliani Albrecht , Pieber Thomas R , Obermayer-Pietsch Barbara , Lerchbaum Elisabeth

Introduction: Osteocalcin (OC) is a marker of bone formation but also seems to play a hormonal role in the regulation of glucose and energy metabolism. Recently, an association of BMI with a haplotype composed of three single nucleotide polymorphisms (SNPs) in the gene for OC, located on chromosome 1q22, was observed in ethnically homogeneous European pedigrees.Aim: The aim of the study was to test the association of these three polymorphisms in the gene...

ba0001pp131 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Effects of zoledronic acid on hormone levels in premenopausal women with breast cancer receiving neoadjuvant or adjuvant chemotherapy and endocrine therapy: Probone II Study

Hadji Peyman , Kauka Anette , Bauer Thomas , Ziller May , Birkholz Katrin , Baier Monika , Muth Mathias , Kann Peter

Introduction: Loss in bone mineral density may occur soon after initiation of adjuvant therapy for hormone-receptor-positive (HR+), breast cancer (BC) and correlates with changes in hormone levels. Adding zoledronic acid (ZOL) to adjuvant treatment for BC can preserve/improve bone mineral density and delay disease recurrence; however, effects of ZOL on endocrine hormone levels are currently unclear.Methods: Probone II assessed the course of endocrine hor...

ba0001pp161 | Cancer and bone: basic, translational and clinical | ECTS2013

Effect of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for breast cancer: the ProBONE II Study

Hadji Peyman , Kauka Anette , Bauer Thomas , Birkholz Katrin , Baier Monika , Muth Mathias Muth , Ziller May

Introduction: Bone mineral density (BMD) evaluations have shown that adjuvant chemotherapy or endocrine therapy (ET) for early breast cancer (BC) is associated with accelerated BMD loss and increased fracture risk. In recent studies, zoledronic acid (ZOL) increased BMD in premenopausal and postmenopausal women with BC, and improved disease-free survival in some patient subsets compared with no ZOL. The purpose of the current study was to investigate the effect of adjuvant trea...

ba0001pp256 | Chondrocytes and cartilage | ECTS2013

Sclerostin preserves chondrocyte maintenance by modulating the crosstalk between canonical and non-canonical Wnt pathways

Bouaziz Wafa , Funck-Brentano Thomas , Lin Hilene , Ea Hang-Korng , Hay Eric , Cohen-Solal Martine

Aim: Wnt/β-catenin pathway promotes cartilage breakdown in osteoarthritis. We have previously shown that sclerostin preserves chondrocyte maintenance in vitro by reducing chondrocyte catabolism through the inhibition of Wnt/β-catenin pathway. However, sclerostin restores partially the expression of the anabolic genes. We therefore investigated the effect of sclerostin in the activation of Wnt non canonical pathways mediated by Ca2+/CaMKII, JNK, an...

ba0001pp257 | Chondrocytes and cartilage | ECTS2013

Stress-induced matrix metalloproteinase production in cartilage does not depend on NALP3-inflammasome in osteoarthritis

Bougault Carole , Gosset Marjolaine , Houard Xavier , Salvat Colette , Godmann Lars , Pap Thomas , Jacques Claire , Berenbaum Francis

Background: Cartilage matrix breakdown in osteoarthritis (OA) is due to mechanical stress and inflammation leading to increased metalloproteinases (MMPs) production. Currently, IL1β is thought to have a major role in this process. IL1β is synthesized as an inactive precursor, which is cleaved into the secreted active form. This maturation process mainly occurs in the inflammasome complex. Inflammasome is constituted by initiators (including NALP3) and adaptor molecul...

ba0001pp350 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

The risk of fractures in cirrhosis and chronic pancreatitis. a danish nationwide retrospective matched cohort study

Bang Ulrich Christian , Benfield Thomas , Bendtsen Flemming , Hyldstrup Lars , Jens-Erik Beck Jensen

Background and aims: Cirrhosis and chronic pancreatitis (CP) are accompanied by inflammation and malnutrition. Both conditions may affect bone metabolism negatively and facilitate bone fractures. The objective of this study was to evaluate the risk of fractures among patients with CP or cirrhosis and the impact of fat malabsorption on fracture risk among patients with CP.Methods: Using the Danish National Patient Register, we did a retrospective cohort s...

ba0001pp432 | Osteoporosis: treatment | ECTS2013

Effects of a mutated sclerostin peptide on bone and lean mass in mice

Gerbaix Maude , Pierroz Dominique , Bonnet Nicolas , Boschert Verena , Mueller Thomas , Ferrari Serge

Sclerostin, a product of osteocytes, is known to inhibit Wnt signaling by binding the LRP5/6 receptor.We investigated the effects of a mutated mouse sclerostin protein (muScl, R118A/R144A) with potential sclerostin antagonistic activity. In vitro, muScl fully competed with wild type sclerostin for binding to LRP6, whereas its IC50 for Wnt3a activity was 4× higher than sclerostin (i.e. 600 nM). Moreover, serum osteocalcin increased in mice a...

ba0002p41 | (1) | ICCBH2013

Management of a new case of neonatal hypocalciuric hypercalcemia related to mutation of the calcium-sensing receptor gene with bone abnormalities

Edouard Thomas , Mouly Celine , Mimoun Emmanuelle , Gennero Isabelle , Magdelaine Corinne , Salles Jean Pierre

Background: A 5-month-old girl was referred to our unit after a systemic screening for hip dislocation by X-rays revealed bilateral femoral bowing. She was the first child of healthy non-consanguineous parents, and her family history was unremarkable. Her parents had a normal physical examination, and normal laboratory findings. At presentation, her height was 64.0 cm (Z-score: 0.0) with a regular height velocity. Weight was 7.4 kg (Z-score: 1.0). On physical...